CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

放疗在复发/难治性非霍奇金淋巴瘤患者 CAR-T 细胞治疗中的作用：当前研究与未来前景

英文原题：Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.

查看英文原题

Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.

PubMed 2024/05/22（内容时间） Crit Rev Oncol Hematol Q1 · IF 6.2（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：CAR-T非霍奇金淋巴瘤地区：中国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

中文摘要

CAR-T 细胞疗法已彻底改变复发/难治性非霍奇金淋巴瘤（R/R NHL）患者的治疗方式，但长期预后仍不理想。此外，亟须解决两个关键问题：CAR-T 输注前降低肿瘤负荷，以及控制 CAR-T 治疗后的致命毒性。放疗（RT）与 CAR-T 联合应用可改善其安全性和疗效。RT 可作为桥接治疗，在 CAR-T 输注前降低肿瘤负荷，从而有助于安全、成功地输注 CAR-T；在 CAR-T 治疗失败时也可作为挽救治疗。本综述旨在讨论支持 RT 用于 R/R NHL 患者 CAR-T 治疗的现有证据。尽管多数研究显示 RT 在 CAR-T 综合治疗中具有积极作用，但二者联合所产生的协同获益仍不确定。此外，最佳剂量和分割方案以及放射反应仍需进一步研究。

展开英文摘要原文

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment approach for patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

However, the long-term prognosis has been discouraging. Moreover, the urgent resolution of two critical issues is necessary: minimize tumor burden before CAR-T infusion and control fatal toxicities post CAR-T therapy. By combining radiotherapy (RT), the safety and efficacy of CAR-T can be improved.

RT can serve as bridging therapy, reducing the tumor burden before CAR-T infusion, thus enabling safe and successful CAR-T infusion, and as salvage therapy in cases of CAR-T therapy failure. This review aims to discuss the current evidence supporting the use of RT in CAR-T therapy for patients with R/R NHL. Although most studies have shown a positive role of RT in combined modality treatments for patients undergoing CAR-T therapy, the synergy gained from these remains uncertain.

Furthermore, the optimal dose/fraction and radiation response require further investigation.

论文信息

作者
Yu L、Zou R、He J、Qu C
第一作者单位
Department of Hematology, the First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou 215000, China; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215000, China. Electronic address: ylz8211@163.com.China
通讯作者单位
Department of Hematology, the First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou 215000, China; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215000, China. Electronic address: qcj310@163.com.China
文献类型
综述
期刊
Critical reviews in oncology/hematology2024 Jul
原文标识
PubMed 38782146　·　DOI 10.1016/j.critrevonc.2024.104390

在 PubMed 查看 → 出版商原文（DOI） 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →